Cognito Therapeutics, Inc.

Cognito Therapeutics, Inc.

is a late clinical-stage neurotechnology company located in Cambridge, Massachusetts. Founded in 2016 by MIT professors Ed Boyden and Li-Huei Tsai, the company focuses on developing non-invasive therapies for neurodegenerative diseases, particularly Alzheimer’s disease. Cognito's innovative approach utilizes induced brain wave oscillations to activate the brain's immune system and reduce harmful markers associated with Alzheimer's. The company's lead product, SpectrisTM, is an at-home therapeutic headset designed to deliver sensory-driven neurostimulation. This device is personalized to individual brain responses and is intended to help preserve cognition, maintain daily function, and slow brain atrophy in patients with mild-to-moderate Alzheimer’s disease. Cognito Therapeutics aims to improve the quality of life for patients through its unique technology, which represents a new category of disease-modifying therapy distinct from traditional pharmaceuticals. The company is advancing Spectris toward FDA submission and commercialization, supported by significant funding and ongoing clinical studies.